Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: A phase 3, open-label extension study (PERSIST)

The Lancet Respiratory Medicine

Volumn 2, Issue 11, 2014, Pages 902-910

  McKone, Edward F ^a,b   Borowitz, Drucy ^c   Drevinek, Pavel ^d   Griese, Matthias ^e,f   Konstan, Michael W ^g   Wainwright, Claire ^h   Ratjen, Felix ^i,j   Sermet Gaudelus, Isabelle ^k   Plant, Barry ^l   Munck, Anne ^m   Jiang, Ying ⁿ   Gilmartin, Geoffrey ⁿ   Davies, Jane C ^o  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^l University College Cork   (Ireland)

^m HÔPITAL ROBERT DEBRÉ   (France)

ⁿ VERTEX PHARMACEUTICALS   (United States)

^o ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; PLACEBO; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; COUGHING; CRACKLE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GENE MUTATION; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTRANSAMINASEMIA; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE OBSTRUCTION; OPEN STUDY; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINOPHARYNGITIS; SINUSITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; GENETICS; MUTATION; PATHOPHYSIOLOGY; RESPIRATORY TRACT INFECTION; TIME; WEIGHT GAIN; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOPHENOLS; CHILD; COUGH; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MUTATION; QUINOLONES; RESPIRATORY TRACT INFECTIONS; TIME FACTORS; WEIGHT GAIN; YOUNG ADULT;

EID: 84918774941     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70218-8     Document Type: Article

References (29)

1. Cutting G, Accurso F, Ramsey B, Welsh M Cystic fibrosis. The Metabolic and Molecular Basis of Inherited Diseases 2012, McGraw-Hill, Health Professions Division, New York. 8th edn. B. Valle, Volgerstein, Kinzler, Antonarakis, Ballabio (Eds.).
2. McKone EF, Emerson SS, Edwards KL, Aitken ML Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003, 361:1671-1676.
3. Cystic Fibrosis Foundation. Patient Registry 2012 Annual Data Report, Bethesda, MD, USA; 2013.
4. ECFS Patient Registry Annual Data Report 2008-09, 2012.
5. Bobadilla JL, Macek M, Fine JP, Farrell PM Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat 2002, 19:575-606.
6. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009, 106:18825-18830.
7. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cystic Fibrosis 2012, 11:237-245.
8. Kalydeco® [US Prescribing Information]. Vertex Pharmaceuticals Incorporated, Boston, MA; 2014.
9. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New Engl J Med 2011, 365:1663-1672.
10. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013, 187:1219-1225.
11. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005, 128:2347-2354.
12. Accurso FJ1, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010, 363:1991-2003.
13. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012, 142:718-724.
14. Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014, 2:527-538.
15. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001, 139:813-820.
16. Konstan MW, Wagener JS, Pasta DJ, et al. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 2011, 46:545-553.
17. Milla CE Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis. Thorax 1998, 53:1014-1017.
18. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. New Engl J Med 1999, 340:23-30.
19. Moss RB Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002, 121:55-63.
20. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Morgan WJ Clinical use of tobramycin inhalation solution (TOBI(R)) shows sustained improvement in FEV in cystic fibrosis. Pediatr Pulmonol 2014, 49:529-536.
21. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010, 182:627-632.
22. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001, 153:345-352.
23. Robson M, Abbott J, Webb K, Dodd M, Walsworth-Bell J A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992, 47:684-689.
24. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002, 121:64-72.
25. Yi MS, Tsevat J, Wilmott RW, Kotagal UR, Britto MT The impact of treatment of pulmonary exacerbations on the health-related quality of life of patients with cystic fibrosis: does hospitalization make a difference?. J Pediatr 2004, 144:711-788.
26. Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012, 40:61-66.
27. Rowe SM, Hetshe SL, Gonske T, et al. Clinical mechanisms of the CFTR potentiator ivacaftor in G551D-medicated CF. Am J Respir Crit Care Med 2014, 190:175-184.
28. Sawicki GS, McKone EF, Pasta DJ, Wagener J, Johnson C, Konstan MW The effect of ivacaftor on the rate of lung function decline in CF patients with a G551D-CFTR mutation. J Cystic Fibrosis 2014, 13:S6.
29. McKone EF, Marshall BC Using registries to improve cystic fibrosis care. ERS Monogr 2014, 64:263-272.